Skip to content

The Effect of Selenium on Thyroid Function and Immune Status in Patients with Hashimoto's Thyroiditis

The Effect of Selenium on Thyroid Function and Immune Status in Patients with Hashimoto's Thyroiditis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098206
Enrollment
Unknown
Registered
2025-03-04
Start date
2025-03-20
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hashimoto Thyroiditis

Interventions

Experimental group:Selenium yeast tablet treatment
control group:conventional therapy

Sponsors

Zhenjiang First People's Hospital (Affiliated People’s Hospital of Jiangsu University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18 years old <= age <= 60 years old; 2.Conforming to the diagnostic criteria of Hashimoto’s thyroiditis (HT) in the "Guidelines for the Diagnosis and Treatment of Thyroid Diseases in China" (2008), with positive serum TPOAb (thyroid peroxidase antibody) and/or TGAb (thyroid globulin antibody);3.The ultrasonographic appearance shows diffuse and heterogeneous hypoechogenic changes within the thyroid gland;4.Hashimoto's thyroiditis (HT) with normal thyroid function, or HT with subclinical hypothyroidism, or HT with various degrees of thyroid dysfunction;5.Newly diagnosed patients with Hashimoto's thyroiditis (HT) who have not received treatment with immunomodulators, vitamins, or other trace elements;6.Patients with good treatment compliance, who are fully informed about this study and have voluntarily signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with other thyroid diseases;2.Pregnant or breastfeeding women;3.Patients who have received treatment with glucocorticoids, immunosuppressants, or traditional Chinese medicine;4.Patients with malignant tumors or psychiatric disorders;5.Patients who have recently received treatment with selenocompounds, immunomodulators, or radioactive iodine;6.Patients with other autoimmune diseases;7.Patients with severe cardiovascular, cerebral, hepatic, or renal diseases, or those with infections, fever, or allergies;8.Patients with poor compliance, incomplete data, or those who withdraw from the study midway.

Design outcomes

Primary

MeasureTime frame
Thyroid function;Proportion of Tfh cells?Relevant cytokines?;

Secondary

MeasureTime frame
Blood selenium concentration;

Countries

China

Contacts

Public ContactLiu Yingzhao

Zhenjiang First People's Hospital (Affiliated People’s Hospital of Jiangsu University)

zjliuyingzhao@126.com+86 511 88917730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026